Assembly Biosciences, Inc. Proceeds from Sale of Available-for-sale Securities
Assembly Biosciences, Inc. (ASMB) reported Proceeds from Sale of Available-for-sale Securities of $48.90 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities · last filed 2019-02-28
- Assembly Biosciences, Inc. proceeds from sale of available-for-sale securities for fiscal 2018 was $48.90M, a 45.97% increase from fiscal 2017.
- Assembly Biosciences, Inc. proceeds from sale of available-for-sale securities for fiscal 2017 was $33.50M, a 24.38% decline from fiscal 2016.
- Assembly Biosciences, Inc. proceeds from sale of available-for-sale securities for fiscal 2016 was $44.30M, a 786.00% increase from fiscal 2015.
- Assembly Biosciences, Inc. proceeds from sale of available-for-sale securities for fiscal 2015 was $5.00M.
| Period end | Proceeds from Sale of Available-for-sale Securities 12 month |
|---|---|
| 2018-12-31 | $48.90M 10-K · filed 2019-02-28 |
| 2017-12-31 | $33.50M 10-K · filed 2019-02-28 |
| 2016-12-31 | $44.30M 10-K · filed 2019-02-28 |
| 2015-12-31 | $5.00M 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |